- Home
- HOND vs FHTX Comparison
HOND vs FHTX Comparison
Compare HOND & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- FHTX
- Stock Information
- Founded
- HOND 2024
- FHTX 2015
- Country
- HOND United States
- FHTX United States
- Employees
- HOND N/A
- FHTX N/A
- Industry
- HOND
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- HOND
- FHTX Health Care
- Exchange
- HOND NYSE
- FHTX Nasdaq
- Market Cap
- HOND 290.9M
- FHTX 237.4M
- IPO Year
- HOND 2024
- FHTX 2020
- Fundamental
- Price
- HOND $10.11
- FHTX $5.23
- Analyst Decision
- HOND
- FHTX Strong Buy
- Analyst Count
- HOND 0
- FHTX 6
- Target Price
- HOND N/A
- FHTX $13.17
- AVG Volume (30 Days)
- HOND 1.5K
- FHTX 163.3K
- Earning Date
- HOND 01-01-0001
- FHTX 03-06-2025
- Dividend Yield
- HOND N/A
- FHTX N/A
- EPS Growth
- HOND N/A
- FHTX N/A
- EPS
- HOND N/A
- FHTX N/A
- Revenue
- HOND N/A
- FHTX $25,515,000.00
- Revenue This Year
- HOND N/A
- FHTX N/A
- Revenue Next Year
- HOND N/A
- FHTX $8.30
- P/E Ratio
- HOND N/A
- FHTX N/A
- Revenue Growth
- HOND N/A
- FHTX N/A
- 52 Week Low
- HOND $9.97
- FHTX $3.86
- 52 Week High
- HOND $11.57
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- FHTX 52.39
- Support Level
- HOND N/A
- FHTX $3.89
- Resistance Level
- HOND N/A
- FHTX $6.27
- Average True Range (ATR)
- HOND 0.00
- FHTX 0.59
- MACD
- HOND 0.00
- FHTX 0.11
- Stochastic Oscillator
- HOND 0.00
- FHTX 48.38
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.